Emerging links between thrombosis, inflammation and cancer: Role of heparin

Acta Chirurgica Belgica

Volumn 105, Issue 3, 2005, Pages 237-248

  Mousa, S A ^a,b  

^a ALBANY COLLEGE OF PHARMACY   (United States)

^b Albany College of Pharmacy   (United States)

Author keywords

Cancer; Heparin; Metastasis

Indexed keywords

ANTITHROMBIN III; CERTOPARIN; CYTOKINE; DALTEPARIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENOXAPARIN; FIBRIN; FIBRINOGEN RECEPTOR; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; PADGEM PROTEIN; REACTIVE OXYGEN METABOLITE; THROMBIN; THROMBOPLASTIN; TINZAPARIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; WARFARIN;

ALLERGIC RHINITIS; ANGINA PECTORIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; BLEEDING; CANCER; CANCER GROWTH; CELL AGGREGATION; CELL FUNCTION; CHEMOTAXIS; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG MECHANISM; ENTERITIS; ESCHERICHIA COLI; HEMOSTASIS; HUMAN; INFECTION; INFLAMMATION; LEUKOCYTE ACTIVATION; LUNG EMBOLISM; LUNG METASTASIS; MELANOMA; METASTASIS; NEUTROPHIL; NONHUMAN; PREDICTION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOCYTE ACTIVATION; THROMBOSIS; TUMOR VASCULARIZATION; ULCERATIVE COLITIS;

EID: 21344448405     PISSN: 00015458     EISSN: 25770160     Source Type: Journal    
DOI: 10.1080/00015458.2005.11679711     Document Type: Review

References (119)

1. WEITZ J. I. Low-molecular-weight heparin. N Engl J Med, 1997, 337 : 688-98.
2. MOUSA S. A., FAREED J. W. Advances in anticoagulant, antithrombotic and thrombolytic drugs. Exp Opin Invest Drugs, 2001, 10 : 157-62.
3. MOUSA S. A. Comparative efficacy among different low molecular weight heparin (LMWHs) & drug interaction : implications in the management of vascular disorders. Thromb Haemost, 2000, 26 (Suppl 1) : 39-46.
4. AGUILAR D., GOLDHABER S. Z. Clinical uses of low molecular weight heparin. Chest, 1999, 115 : 1418-23.
5. TAHERI S. A., LAZAR L., HADDAD G., CASTALDO R., WILSON M., MOUSA S. Diagnosis of deep venous thrombosis by use of soluble necrosis factor receptor. Angiology, 1998, 49 : 537-41.
6. NELSON R. M., CECCONI O., ROBERTS W. G., ARUFFO A., LINHARDT R. J., BEVILACQUA M. P. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood, 1993, 82 : 3253-8.
7. LANTZ M., THYSELL H., NILSSON E., OLSSON I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest, 1991, 88 : 2026-31.
8. TYRELL D. J., KILFEATHER S., PAGE C. P. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci, 1995, 16 : 198-204.
9. HOCKING D., FERRO T. J., JOHNSON A. Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J Appl Physiol, 1992, 72 : 179-85.
10. DARIEN B. J., FAREED J., CENTGRAF K. S., et al. Low molecular weight heparin prevents the pulmonary hemodynamic and pathomorphologic effects of endotoxin in a porcine acute lung injury model. Shock, 1998, 9 : 274-81.
11. MEYER J., COX C. S., HERNDON D. N., et al. Heparin in experimental hyperdynamic sepsis. Crit Care Med, 1993, 21 : 84-9.
12. HIEBERT L. M., LIU J. M. Heparin protects cultured arterial endothelial cells from damage by toxic oxygen metabolites. Atherosclerosis, 1990, 83 : 47-51.
13. MATZNER Y., MARX G., DREXLER R., ELDOR A. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis. Thromb Haemost 1984, 52 : 134-7.
14. BAZZONI G., BELTRAN NUNEZ A., MASCELLANI G., BIANCHINI P., DEJANA E., DEL MASCHIO A. Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med, 1993, 121 : 268-75.
15. VANCHERI C., MASTRUZZO C., ARMATO F., et al. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol, 2001, 108 : 703-8.
16. DIAMANT Z., TIMMERS M. C., VAN DER VEEN H., PAGE C. P., VAN DER MEER F. J., STERK P. J. Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am J Respir Crit Care Med, 1996, 153 : 1790-5.
17. GARRIGO J., DANTA I., AHMED T. Time course of the protective effect of inhaled heparin on exercise-induced asthma. Am J Respir Crit Care Med, 1996, 153 : 1702-7.
18. GAFFNEY A., GAFFNEY P. Rheumatoid arthritis and heparin. Br J Rheumatol, 1996, 35 : 808.
19. BOWLER S. D., SMITH S. M., LAVERCOMBE P. S. Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis, 1993, 147 : 160-3.
20. DWARAKANATH A. D., YU L. G., BROOKES C., PRYCE D., RHODES J. M. Sticky neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut, 1995, 37 : 585-8.
21. PETTTOU M., HÉRAULT J.-P., BERNAT A., et al. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature, 1999, 398 : 417-22.
22. TYRREL D. J., HORNE A. P., HOLME K. R., PREUSS J. M. H., PAGE C. P. Heparin in inflammation : potential therapeutic applications beyond anticoagulation. Adv Pharmacol, 1999,46 : 151-208.
23. SALAS A., SANS M., SORIANO A., et al. Heparin attenuates TNF-α induced inflammatory response through a CDlIb dependent mechanism. Gut, 2000, 47 : 88-96.
24. PANÉS J., PERRY M., GRANGER D. N. Leukocyte-endothelial cell adhesion : avenues for therapeutic intervention. Br J Pharmacol, 1999, 126 : 537-50.
25. LEVER R., HOULT J. R. S., PAGE C. P. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leukocytes to vascular endothelium in vitro. Br J Pharmacol, 2000, 129 : 533-40.
26. GAFFNEY P. R., DOYLE C. T., GAFFNEY A., HOGAN J., HAYES D. P., ANNIS P. Paradoxical response to heparin in 10 patients with ulcerative colitis. Am J Gastroenterology, 1995, 90 : 220-3.
27. GAFFNEY P., GAFFNEY A. Heparin therapy in refractory ulcerative colitis - an update. Gastroenterology, 1996, 110 : A913.
28. EVANS R. C., RHODES J. M. Treatment of corticosteroid-resistant ulcerative colitis with heparin : a report of nine cases. Gut, 1995, 37 : A49.
29. BRAZIER F., YZET T., DUCHMANN J. C., et al. Effect of heparin treatment on extra intestinal manifestations associated with inflammatory bowel diseases. Gastroenterology, 1996, 110 : A872.
30. BRAZIER F., YZET T., BORUCHOWICZ A., et al. Treatment of ulcerative colitis with heparin. Gastroenterology, 1996, 110 : A872.
31. DUPAS J. L., BRAZIER F., YZET T., et al. Treatment of active Crohn's disease with heparin. Gastroenterology, 1996, 110 : A900.
32. FOLWACZNY C., SPANNAGL M., WIEBECKE W., et al. Heparin in the treatment of highly active inflammatory bowel disease (IBD). Gastroenterology, 1996, 110 : A908 [abstract].
33. DWARAKANATH A. D., YU L. G., BROOKES C., PRYCE D., RHODES J. M. "Sticky" neutrophils, pathergic arthritis, and response to heparin in pyoderma gangrenosum complicating ulcerative colitis. Gut, 1995, 37 : 585-8.
34. TEIXEIRA M. M., HELLEWELL P. G. Suppression by intradermal administration of heparin of eosinophil accumulation but not edema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol, 1993, 110 : 1496-500.
35. CARR J. The anti-inflammatory action of heparin : heparin as an antagonist to histamine, bradykinin and prostaglandin E1. Thromb Res 1979, 16 : 507-16.
36. KOENIG A., NORGARD-SUMNICHT K., LINHARDT R., VARKI A. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins : implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest, 1998, 101 : 877-89.
37. DIAMOND M. S., ALON R., PARKOS C. A., QUINN M. T., SPRINGER T. A. Heparin is an adhesive ligand for the leukocyte integral Mac-1 (CD11b/CD18). J Cell Biol, 1995, 130 : 1473-82.
38. BENIMETSKAYA L., LOIKE J. D., KHALED Z., et al. Mac-1 (CD11b/CD18) is an oligodeoxy-nucleotide-binding protein. Nat Med, 1997, 3 : 414-20.
39. HIRSH J., LEVINE M. N. Low molecular weight heparin. Blood, 1992, 79 : 1-17.
40. NIELSEN J. I., OSTERGAARD P. Chemistry of heparin and low molecular weight heparin. Acta Chir Scand Suppl 1988, 543 : 52-6.
41. LINHARDT R. J., GUNAY N. S. Production and chemical processing of low molecular weight heparins. Semin Thromb Haemost, 1999, 25 : 5-16.
42. EMMANUELE R. M., FAREED J. The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987, 48 : 591-6.
43. BRIEGER D., DAWES J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost, 1997, 77 : 317-22.
44. MOUSA S. A., MOHAMED S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost, 2004, 92 : 627-33.
45. MOUSA S. A., KAISER B. Tissue factor pathway inhibitor in thrombosis and beyond : role of heparin. Drugs of the Future, 2004, 29 : 751-66.
46. BONEU B., CARANOBE C., CADROY Y., et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988, 14 : 18-27.
47. SUTOR A. H., MASSICOTTE P., LEAKER M., ANDREW M. Heparin therapy in pediatric patients. Semin Thromb Hemost, 1997, 23 : 303-19.
48. MAJERUS P., BROZE J. G., MILETICH J. Anticoagulant, thrombolytic and antiplatelet drugs. In: HARDMAN J., LIMBIRD L., MOLINOFF P., RUDDON R., GOODMAN A. (eds.). Goodman & Gilman's, the pharmacological basis of therapeutics. 9th edition. New York : McGraw-Hill,, 1996 : 1341-59.
49. SILVERSTEIN R. Drugs affecting hemostosis. In: MUNSON P, MUELLER R, BREEZE G, eds. Munson's principles of pharmacology. New York : Chapman & Hall,, 1995 : 1123-43.
50. THEROUX P., WATERS D., QIU S., MCCANS J., DE GUISE P., JUNEAU M. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation, 1993, 88 : 2045-8.
51. ITOH K., NAKAO A., KISHIMOTO W., TAKAGI H. Heparin effects on superoxide production by neutrophils. Eur Surg Res, 1995 ; 27 : 184-8.
52. ATTANASIO M., GORI A. M., GIUSTI B., et al. Cytokine gene expression in human LPS- and IFNgamma-stimulated mononuclear cells is inhibited by heparin. Thromb Haemost, 1998, 79 : 959-62.
53. DANDONA P., QUTOB T., HAMOUDA W., BAKRI F., ALJADA A., KUMBKARNI Y. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res, 1999, 96 : 437-43.
54. FRIEDRICHS G. S., KILGORE K. S., MANLEY P. J., GRALINSKI M. R., LUCCHESI B. R. Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ Res, 1994, 75 : 701-10.
55. BLACK S. C., GRALINSKI M. R., FRIEDRICHS G. S., KILGORE K. S., DRISCOLL E. M., LUCCHESI B. R. Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc Res, 1995, 29 : 629-36.
56. LUCCHESI B. R., KILGORE K. S. Complement inhibitors in myocardial ischemia/reperfusion injury. Immunopharmacology, 1997, 38 : 27-42.
57. HAWARI F. I., SHYKOFF B. E., Izzo J. L. Jr. Heparin attenuates norepinephrine-induced venoconstriction. Vasc Med, 1998, 3 : 95-100.
58. DE CATERINA R., LIBBY P., PENG H. B., et al. Nitric oxide decreases cytokine-induced endothelial activation : nitric oxide selectively reduces endothelial expression of adhesion molecules and pro-inflammatory cytokines. J Clin Invest, 1995, 96 : 60-8.
59. TROUSSEAU A. Phlegmasia alba dolens. In: BAILLIER JB, ed. Clinique de l'Hotel-Dieu de Paris, 2nd ed. London: New Sydenham Society, 1865 ; Chapter 3 : 94. [Key historical observation linking thrombosis and cancer.]
60. SCHILLER H., BARTSCHT T., ARLT A., et al. Thrombin as a survival factor for cancer cells : thrombin activation in malignant effusions in vivo and inhibition of idarubicin-induced cell death in vitro. Int J Clin Pharmacol Ther, 2002, 40 : 329-35.
61. SORENSEN H., MELLEMKJAER L., OLSEN J., et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med, 2000, 343 : 1846-50.
62. CAINE G. J., LIP G. Y. Anticoagulants as anticancer agents? Lancet Oncol, 2002, 3 : 591-2.
63. LEBEAU B., CHASTANG C., BRECHOT J.-M., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer, 1994, 74 : 38-45. [Key clinical observation defining benefits of anticoagulation in the enhancement of chemo response rate and improved clinical outcome.]
64. CHAHINIAN A., PROPERT K., WARE J., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 1989, 7 : 993-1002.
65. THORNES R. Coumarins, melanoma and cellular immunity. In : MCBRIEN D, SLATOR T, eds. Protective agents in cancer. London : Academic Press, 1983 : 43-56.
66. SABA H. I., KHALIL F. K., MORELLI G. A., et al. Thromboembolism preceding cancer : a correlation study. Am J Hematol, 2003, 72 : 109-14.
67. GOLDBERG R. J., SENEFF M., GORE J. M. Occult malignant neoplasm in patients with deep venous thrombosis. Ann Intern Med 1987, 147 : 251-3.
68. BARON J. A., GRIDLEY G., WEIDERPASS E., et al. Venous thromboembolism and cancer. Lancet, 1998, 351 : 1077-80.
69. RICKLES F. R., EDWARDS R. L. Activation of blood coagulation in cancer : Trousseau's syndrome revisited. Blood 1982, 62 : 14-31.
70. LEVINE M. N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost, 1997, 78 : 133-6.
71. FALANGA A. Mechanisms of hypercoagulation in malignancy and during chemotherapy. Haemostasis, 1998, 28 : 50-60.
72. KAKKAR A. J., DE RUVO N., TEBBUTT S., et al. Extrinsic pathway activation with elevated tissue factor and factor VIIa in patients with cancer. Lancet, 1995, 346 : 1004-5.
73. SIMONNEAU G., SORS H., CHARBONNIER B., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med, 1997, 337 : 663-9.
74. KOOPMAN M. M. W., PRANDONI P., PIOVELLA F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med, 1996, 334 : 682-7.
75. PINTUCCI G., FROUM S., PINNELL J., et al. Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost, 2002, 88 : 834-42.
76. MANEGOLD P. C., HUTTER J., PAHERNIK S. A., et al. Platelet-endothelial interaction in tumor angiogenesis and microcirculation. Blood, 2003, 101 : 1970-6.
77. WERTHER K., CHRISTENSEN I. J., NIELSEN H. J. Determination of vascular endothelial growth factor (VEGF) in circulating blood : significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest, 2002, 62 : 343-50.
78. VERHEUL H. M., PINEDO H. M. Tumor growth : a putative role for platelets? Oncologist, 1998, 3(2) : II.
79. VERHEUL H. M., HOEKMAN K., LUYKX-DE BAKKER S., et al Platelet : transporter of vascular endothelial growth factor. Clin Cancer Res, 1997, 3 (12 Pt 1) : 2187-90.
80. AMIRKHOSRAVI A., AMAYA M., DESAI H., et al. Latelet-CD40 ligand interaction with melanoma cell and monocyte CD40 enhances cellular pro-coagulant activity. Blood Coagul Fibrinolysis, 2002, 13 : 505-12.
81. GASIC G. J., GASIC T. B., STEWART C. C. Anti-metastatic effect associated with platelet reduction. Pathology, 1998, 61 : 46-52.
82. KARPATKIN S., PEARLSTEIN E., AMBROGIO C., et al. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988, 81 : 1012-9.
83. TRIKHA M., ZHOU Z., TIMAR J., et al. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis. Cancer Res, 2002, 62 : 2824-33.
84. VARKI N. M., VARKI A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost, 2002, 28 : 53-66.
85. KAKKAR A. J., WILLIAMSON R. C. Prevention of venous thromboembolism in cancer using low molecular weight heparin. Haemostasis, 1997, 27(Suppl 1) : 32-7.
86. ZACHARSKI L. R., ORNSTEIN D. L. Heparin and cancer. Thromb Haemost, 1998, 80 : 10-23.
87. VON TEMPELHOFF G. F., HARENBERG J., NEIMANN F., et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery : a prospective randomized double-blind trial. Int Oncol, 2000, 16 : 815-24. [Key double blind trial illustrating the survival benefits of LMWH over UFH post-surgery in ovarian and uterine but not breast cancer (well defined tumor type).]
88. ZACHARSKI L. R. Anticoagulant in cancer treatment : malignancy as a solid phase coagulopathy. Cancer Lett, 2002, 186 : 1-9.
89. MEYERS G., MARJANOVIC Z., VALCKE J., et al. Comparison of LMWH and wafarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med, 2002, 162 : 1729-35.
90. MOUSA S. A. Anticoagulants in thrombosis and cancer : the missing link. Semin Thromb Haemost, 2002, 28 : 45-52.
91. TROUSSEAU A. Plegmasia alba dolens. In : BAILLIER J. B. (ed.). Clinique de l'Hotel-Dieu de Paris, 2nd ed. London : New Syndenham Society, 1865 ; Chapter 3 : 654-712.
92. HAWARD W. Phlebitis and thrombosis. Lancet 1906, 1 : 650-5.
93. DVORAK H. F. Thrombosis and cancer. Hum Pathol 1987, 18 : 275-84.
94. KAKKAR A. K., LEVINE M. N., PRANDONI P., et al. What is the role for antithrombotics in cancer care? Interactive session with panel discussion. Cancer Treat Rev, 2002, 28 : 157-9.
95. DVORAK H. F., SENGER D. R., DVORAK A. M. Fibrin as a component of the tumor stroma : origins and biological significance. Cancer Metastasis Rev 1983, 2 : 41-73.
96. HULL R. D., RASKOB G. E., PINEO G. F., et al. Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med, 1992, 326 : 975-82. [This is a key double blind clinical trial comparing the efficacy and safety of LMWH to UFH in-patients with VTE].
97. LEVINE M., HIRSH J., GENT M., et al Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet, 1994, 343 : 886-9.
98. MOUSA S. A., MOUSA A. S. Angiogenesis inhibitors : current and future directions. Curr Pharmaceutical Design, 2004, 10 : 1-9.
99. MOUSA S. A., MOHAMED S. Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin : anti-cancer efficacy. Oncol Rep, 2004, 12 : 683-8.
100. FOLKMAN J., SHING Y. Control of angiogenesis by heparin and other sulfated polysaccharides. Adv Exp Med Biol, 1992, 313 : 355-64.
101. AMIRKHOSRAVI A., MOUSA S. A., AMAYA M., et al. Antimetastatic effect of tinzaparin, a low molecular weight heparin. J Thromb Haemost, 2003, 1 : 1972-6.
102. LUDWIG R. J., BOEHME B., PODDA M., et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res, 2004, 64 : 2743-50.
103. FALANGA A., RICKLES F. R. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost, 1999, 25 : 173-82.
104. MARKUS G. The role of haemostasis and fibrinolysis in the metastatic spread of cancer. Thromb Haemost 1984, 10 : 61-72.
105. RUF W., MUELLER B. M. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol, 1996, 3 : 379-84.
106. PAREDES N., XU L., BERRY L. R., et al. The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces. Br J Haematol, 2003, 120 : 315-24.
107. PINEDO H., VERHEUL H., D'AMATO R., et al. Involvement of platelets in tumor angiogenesis? Lancet, 1998, 352 : 1775-7.
108. CHAMBERS A. F., MACDONALD I. C., SCHMIDT E. E., et al. Steps in tumor metastasis : new concepts from intra-vital video microscopy. Cancer Metastasis Rev, 1995, 14 : 279-301.
109. WOJTUKIEWICZ M., ZACHARSKI L., MEMOLI V., et al. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res, 1990, 10 : 579-82.
110. ZACHARSKI L., WOJTUKIEWICZ M., COSTANTINI V., et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemostasis, 1992, 18 : 104-16.
111. ZHANG Y., DENG Y., LUTHER T., et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumor cells in mice. J Clin Invest, 1994, 94 : 1320-7.
112. ENGELBERG H. Actions of heparin in the atherosclerotic process. Pharmacol Rev, 1996, 48 : 327-52.
113. BORSIG L., WONG R., FERAMISCO J., et al. Heparin and cancer revisited : mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA, 2001, 98 : 3352-7. [Key study linking heparin to platelet-tumor interactions and metstasis.]
114. CHAMBERS A. F. The metastatic process : basic research and clinical implications. Oncol Res, 1999, 11 : 161-8.
115. MOUSA S. A. Anticoagulants in thrombosis and cancer : the missing link. Expert Rev Anticancer Ther, 2002, 2 : 227-33.
116. VARKI A., VARKI N. M. P-selectin, carcinoma metastasis and heparin : novel mechanistic connections with therapeutic implications. Braz J Med Biol Res, 2001, 34 : 711-7.
117. ENGELBERG H. Actions of heparin that may affect the malignant process. Cancer, 1999, 85 : 257-72.
118. RICKLES F. R., LEVINE M. N. Epidemiology of thrombosis in cancer. Acta Haematol, 2001, 106 : 6-12.
119. MOUSA S. A. Prevention and treatment of tumor growth, metastsis, and thrombembolic complications in cancer patients. US Patent, 2002, 10/125, 882.